These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34197281)

  • 21. Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.
    Ozdarendeli A; Sezer Z; Pavel STI; Inal A; Yetiskin H; Kaplan B; Uygut MA; Bayram A; Mazicioglu M; Unuvar GK; Yuce ZT; Aydin G; Aslan AF; Kaya RK; Koc RC; Ates I; Kara A
    Vaccine; 2023 Jan; 41(2):380-390. PubMed ID: 36460536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.
    Meng FY; Gao F; Jia SY; Wu XH; Li JX; Guo XL; Zhang JL; Cui BP; Wu ZM; Wei MW; Ma ZL; Peng HL; Pan HX; Fan L; Zhang J; Wan JQ; Zhu ZK; Wang XW; Zhu FC
    Signal Transduct Target Ther; 2021 Jul; 6(1):271. PubMed ID: 34267185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents.
    Frenck RW; Klein NP; Kitchin N; Gurtman A; Absalon J; Lockhart S; Perez JL; Walter EB; Senders S; Bailey R; Swanson KA; Ma H; Xu X; Koury K; Kalina WV; Cooper D; Jennings T; Brandon DM; Thomas SJ; Türeci Ö; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2021 Jul; 385(3):239-250. PubMed ID: 34043894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.
    Zhu FC; Li YH; Guan XH; Hou LH; Wang WJ; Li JX; Wu SP; Wang BS; Wang Z; Wang L; Jia SY; Jiang HD; Wang L; Jiang T; Hu Y; Gou JB; Xu SB; Xu JJ; Wang XW; Wang W; Chen W
    Lancet; 2020 Jun; 395(10240):1845-1854. PubMed ID: 32450106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
    Chen GL; Qiu YZ; Wu KQ; Wu Y; Wang YH; Zou YY; Peng CG; Zhao J; Su C; Ma JH; Ni SN; Wang X; Jin TH; Jiang Q; Guo T; Xu Y; Huang CC; Zhang Q; Liu KL; Ji L; Yang HY; Li CL; Su YW; Lu X; Li LJ
    Hum Vaccin Immunother; 2023 Dec; 19(3):2285089. PubMed ID: 38111106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
    Dinh Thiem V; Van Anh PT; Van Men C; Hung DT; Pollard AJ; Kamitani A; Tada Y; Fukuyama H; Iwasaki Y; Ariyasu M; Sonoyama T
    Vaccine; 2024 Jun; 42(17):3699-3709. PubMed ID: 38734495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and immunogenicity of heterologous boost immunization with an adenovirus type-5-vectored and protein-subunit-based COVID-19 vaccine (Convidecia/ZF2001): A randomized, observer-blinded, placebo-controlled trial.
    Jin P; Guo X; Chen W; Ma S; Pan H; Dai L; Du P; Wang L; Jin L; Chen Y; Shi F; Liu J; Xu X; Zhang Y; Gao GF; Chen C; Feng J; Li J; Zhu F
    PLoS Med; 2022 May; 19(5):e1003953. PubMed ID: 35617368
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
    Sonoyama T; Iwata S; Shinkai M; Iwata-Yoshikawa N; Shiwa-Sudo N; Hemmi T; Ainai A; Nagata N; Matsunaga N; Tada Y; Homma T; Omoto S; Yokokawa Shibata R; Igarashi K; Suzuki T; Hasegawa H; Ariyasu M
    Vaccine; 2023 Mar; 41(11):1834-1847. PubMed ID: 36572603
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of heterologous boosting against SARS-CoV-2 using a recombinant interferon-armed fusion protein vaccine (V-01): a randomized, double-blind and placebo-controlled phase III trial.
    Wang XY; Mahmood SF; Jin F; Cheah WK; Ahmad M; Sohail MA; Ahmad W; Suppan VK; Sayeed MA; Luxmi S; Teo AH; Lee LY; Qi YY; Pei RJ; Deng W; Xu ZH; Yang JM; Zhang Y; Guan WX; Yu X
    Emerg Microbes Infect; 2022 Dec; 11(1):1910-1919. PubMed ID: 35686572
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and Immunogenicity of a Recombinant Adenovirus Type-5-Vectored Coronavirus Disease 2019 (COVID-19) Vaccine With a Homologous Prime-Boost Regimen in Healthy Participants Aged ≥6 Years: A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Trial.
    Zhu F; Jin P; Zhu T; Wang W; Ye H; Pan H; Hou L; Li J; Wang X; Wu S; Wang Y; Gou J; Huang H; Wu H; Wang X; Chen W
    Clin Infect Dis; 2022 Aug; 75(1):e783-e791. PubMed ID: 34551104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
    Mohazzab A; Fallah Mehrabadi MH; Es-Haghi A; Kalantari S; Mokhberalsafa L; Setarehdan SA; Sadeghi F; Rezaei Mokarram A; Haji Moradi M; Razaz SH; Taghdiri M; Ansarifar A; Lotfi M; Khorasani A; Nofeli M; Masoumi S; Boluki Z; Erfanpoor S; Bagheri Amiri F; Esmailzadehha N; Filsoof S; Mohseni V; Ghahremanzadeh N; Safari S; Shahsavan M; Bayazidi S; Raghami Derakhshani M; Rabiee MH; Golmoradi-Zadeh R; Khodadoost B; Solaymani-Dodaran M; Banihashemi SR
    J Pharm Sci; 2023 Dec; 112(12):3012-3021. PubMed ID: 37832918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety, tolerability and immunogenicity of Biological E's CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 study.
    Thuluva S; Paradkar V; Gunneri S; Yerroju V; Mogulla RR; Suneetha PV; Turaga K; Kyasani M; Manoharan SK; Adabala S; Sri Javvadi A; Medigeshi G; Singh J; Shaman H; Binayke A; Zaheer A; Awasthi A; Narang M; Nanjappa P; Mahantshetti N; Swarup Garg B; Pandey AK
    Vaccine; 2022 Nov; 40(49):7130-7140. PubMed ID: 36328879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunogenicity and safety of a recombinant Omicron BA.4/5-Delta COVID-19 vaccine ZF2202-A in Chinese adults.
    Hu H; Ma F; Gong L; Wang Y; Xu M; Sun H; Hu Q; Wang P; Han L; Xie H
    Vaccine; 2024 May; 42(15):3522-3528. PubMed ID: 38704251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
    Stephenson KE; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Truyers C; Atyeo C; Loos C; Chandrashekar A; McMahan K; Tostanoski LH; Yu J; Gebre MS; Jacob-Dolan C; Li Z; Patel S; Peter L; Liu J; Borducchi EN; Nkolola JP; Souza M; Tan CS; Zash R; Julg B; Nathavitharana RR; Shapiro RL; Azim AA; Alonso CD; Jaegle K; Ansel JL; Kanjilal DG; Guiney CJ; Bradshaw C; Tyler A; Makoni T; Yanosick KE; Seaman MS; Lauffenburger DA; Alter G; Struyf F; Douoguih M; Van Hoof J; Schuitemaker H; Barouch DH
    JAMA; 2021 Apr; 325(15):1535-1544. PubMed ID: 33704352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates.
    Walsh EE; Frenck RW; Falsey AR; Kitchin N; Absalon J; Gurtman A; Lockhart S; Neuzil K; Mulligan MJ; Bailey R; Swanson KA; Li P; Koury K; Kalina W; Cooper D; Fontes-Garfias C; Shi PY; Türeci Ö; Tompkins KR; Lyke KE; Raabe V; Dormitzer PR; Jansen KU; Şahin U; Gruber WC
    N Engl J Med; 2020 Dec; 383(25):2439-2450. PubMed ID: 33053279
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and immunogenicity of a recombinant receptor-binding domain-based protein subunit vaccine (Noora vaccine™) against COVID-19 in adults: A randomized, double-blind, placebo-controlled, Phase 1 trial.
    Salimian J; Ahmadi A; Amani J; Olad G; Halabian R; Saffaei A; Arabfard M; Nasiri M; Nazarian S; Abolghasemi H; Alishiri G
    J Med Virol; 2023 Feb; 95(2):. PubMed ID: 36029105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interim analysis from a phase 2 randomized trial of EuCorVac-19: a recombinant protein SARS-CoV-2 RBD nanoliposome vaccine.
    Lovell JF; Baik YO; Choi SK; Lee C; Lee JY; Miura K; Huang WC; Park YS; Woo SJ; Seo SH; Kim JO; Song M; Kim CJ; Choi JK; Kim J; Choo EJ; Choi JH
    BMC Med; 2022 Nov; 20(1):462. PubMed ID: 36447243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
    Pérez-Rodríguez S; de la Caridad Rodríguez-González M; Ochoa-Azze R; Climent-Ruiz Y; Alberto González-Delgado C; Paredes-Moreno B; Valenzuela-Silva C; Rodríguez-Noda L; Perez-Nicado R; González-Mugica R; Martínez-Pérez M; Sánchez-Ramírez B; Hernández-García T; Díaz-Machado A; Tamayo-Rodríguez M; Martín-Trujillo A; Rubino-Moreno J; Suárez-Batista A; Dubed-Echevarría M; Teresa Pérez-Guevara M; Amoroto-Roig M; Chappi-Estévez Y; Bergado-Báez G; Pi-Estopiñán F; Chen GW; Valdés-Balbín Y; García-Rivera D; Verez-Bencomo V
    Vaccine; 2022 Mar; 40(13):2068-2075. PubMed ID: 35164986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II randomized, double blind, placebo controlled, clinical trial of safety and immunogenicity of an inactivated SARS-CoV-2 vaccine FAKHRAVAC in adults aged 18-70 years.
    Gholami F; Hamidi Farahani R; Karimi Rahjerdi A; Ahi M; Sheidaei A; Gohari K; Rahimi Z; Ansarifar A; Basiri P; Moradi M; Jahangiri A; Naderi K; Ghasemi S; Khatami P; Honari M; Khodaverdloo S; Shooshtari M; Mehr Azin H; Moradi S; Shafaghi B; Allahyari H; Monazah A; Khodaei Poor A; Taghva Z; Bakhshande H; Karimi Nia M; Solaymani Dodaran M; Forooghizade M
    BMC Infect Dis; 2023 Feb; 23(1):118. PubMed ID: 36829111
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity and Safety of a SARS-CoV-2 Inactivated Vaccine KCONVAC in Chinese Children: Randomized, Double-blind, Placebo-controlled Phase 1 and 2 Trials.
    Liu J; Huang B; Li G; Huang T; Wang D; Zhang L; Deng Y; Chang X; Liu Y; Li W; Zhang S; Huang W; Tan W; Gao L
    Pediatr Infect Dis J; 2023 Dec; 42(12):1136-1142. PubMed ID: 37967148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.